These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 18586494)

  • 1. The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice.
    Wang J; Figurski M; Shaw LM; Burckart GJ
    Transpl Immunol; 2008 Jul; 19(3-4):192-6. PubMed ID: 18586494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal glucuronidation and multidrug resistance protein 2-/ multidrug resistance protein 4-mediated efflux of mycophenolic acid: interaction with cyclosporine and tacrolimus.
    El-Sheikh AA; Koenderink JB; Wouterse AC; van den Broek PH; Verweij VG; Masereeuw R; Russel FG
    Transl Res; 2014 Jul; 164(1):46-56. PubMed ID: 24486136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2.
    Hesselink DA; van Hest RM; Mathot RA; Bonthuis F; Weimar W; de Bruin RW; van Gelder T
    Am J Transplant; 2005 May; 5(5):987-94. PubMed ID: 15816878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.
    Naesens M; Kuypers DR; Streit F; Armstrong VW; Oellerich M; Verbeke K; Vanrenterghem Y
    Clin Pharmacol Ther; 2006 Nov; 80(5):509-21. PubMed ID: 17112807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients.
    Colom H; Lloberas N; Andreu F; Caldés A; Torras J; Oppenheimer F; Sanchez-Plumed J; Gentil MA; Kuypers DR; Brunet M; Ekberg H; Grinyó JM
    Kidney Int; 2014 Jun; 85(6):1434-43. PubMed ID: 24402086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus.
    Patel CG; Harmon M; Gohh RY; Akhlaghi F
    Ther Drug Monit; 2007 Feb; 29(1):87-95. PubMed ID: 17304155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of mycophenolic acid and its glucuronide after a single and multiple oral dose of mycophenolate mofetil in Chinese renal transplantation recipients.
    Liang MZ; Lu YP; Nan F; Li YP
    Transplant Proc; 2006 Sep; 38(7):2044-7. PubMed ID: 16979994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil.
    Jain AB; Hamad I; Zuckerman S; Zhang S; Warty VS; Fung JJ; Venkataramanan R
    Liver Transpl Surg; 1999 Mar; 5(2):101-6. PubMed ID: 10071348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats.
    Kobayashi M; Saitoh H; Kobayashi M; Tadano K; Takahashi Y; Hirano T
    J Pharmacol Exp Ther; 2004 Jun; 309(3):1029-35. PubMed ID: 14978191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine.
    Westley IS; Brogan LR; Morris RG; Evans AM; Sallustio BC
    Drug Metab Dispos; 2006 Feb; 34(2):261-6. PubMed ID: 16272406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients.
    Yau WP; Vathsala A; Lou HX; Zhou S; Chan E
    J Clin Pharmacol; 2009 Jun; 49(6):684-99. PubMed ID: 19386625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
    Lobritto SJ; Rosenthal P; Bouw R; Leung M; Snell P; Mamelok RD
    Liver Transpl; 2007 Nov; 13(11):1570-5. PubMed ID: 17969194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of poloxamer 407-induced hyperlipidemia on hepatic multidrug resistance protein 2 (Mrp2/Abcc2) and the pharmacokinetics of mycophenolic acid in rats.
    Kwon MH; Yoon JN; Baek YJ; Kim YC; Cho YY; Kang HE
    Biopharm Drug Dispos; 2016 Sep; 37(6):352-65. PubMed ID: 27241939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
    Cremers S; Schoemaker R; Scholten E; den Hartigh J; König-Quartel J; van Kan E; Paul L; de Fijter J
    Br J Clin Pharmacol; 2005 Sep; 60(3):249-56. PubMed ID: 16120063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus.
    Patel CG; Ogasawara K; Akhlaghi F
    Xenobiotica; 2013 Mar; 43(3):229-35. PubMed ID: 22934787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporine alters correlation between free and total mycophenolic acid in kidney transplant recipients in the initial phase.
    Mino Y; Naito T; Otsuka A; Takayama T; Ozono S; Kagawa Y; Kawakami J
    J Clin Pharm Ther; 2011 Apr; 36(2):217-24. PubMed ID: 21366651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients.
    Hummel M; Yonan N; Ross H; Miller LW; Sechaud R; Balez S; Koelle EU; Gerosa G;
    Clin Transplant; 2007; 21(1):18-23. PubMed ID: 17302587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation.
    Cattaneo D; Perico N; Gaspari F; Gotti E; Remuzzi G
    Kidney Int; 2002 Sep; 62(3):1060-7. PubMed ID: 12164891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.